Pharmacogenetics and cancer therapy.
Pharmacogenetics is the study of how genetic variations affect drug response. These variations can affect a patient's response to cancer drugs, for which there is usually a fine line between a dosage that has a therapeutic effect and one that produces toxicity. Gaining better insight into the genetic elements of both the patient and the tumour that affect drug efficacy will eventually allow for individualized dosage determination and fewer adverse effects.
Relling
M V
MV
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. mary.relling@stjude.org
Dervieux
T
T
D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics; D001711:Biotransformation / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics; D005493:Folic Acid Antagonists / Q000493:pharmacokinetics; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D008780:Methyltransferases / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011955:Receptors, Drug / Q000235:genetics; D014166:Transferases / Q000235:genetics
D018528:ATP-Binding Cassette Transporters; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D005493:Folic Acid Antagonists; D011955:Receptors, Drug; D003577:Cytochrome P-450 Enzyme System; D014166:Transferases; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase